You can rank #1 on Google and still be invisible in AI search.

Pharma brand teams won the SEO game just in time for the game to move. Here is the process we use to get branded sites cited by AI engines without breaking MLR.

The click that never happens

An oncology brand we work with had the rankings every SEO program chases. Position one on its branded terms, page one on its condition terms, clean technical health. By every traditional measure, the search program was finished.

Then we ran the same priority queries through the AI layer. The brand appeared in almost none of the AI-generated answers sitting above its own blue link. The answers were assembled from third-party sources: advocacy sites, reference publishers, a competitor’s unbranded content.

Priority queries in a recent brand-site audit 19 triggered an AI Overview 3 86% of the queries this brand cares about are answered before the click. Source: PharmaForward brand-site AEO audit, 22 priority queries, 2026.

This is the structural shift. Patients and HCPs increasingly read a synthesized answer before they reach any website, and for a growing share of queries there is no click at all. Search demand did not shrink. It moved upstream of your site, into answers your content either feeds or doesn’t.

Why brand sites lose to answer engines

Answer engines cite content that is extractable, structured, and corroborated. A regulated brand site is, by design, none of these. Every sentence has been through claim review, so language is cautious and compound. Definitional content gets pushed off-page to avoid review cycles. Page structure serves navigation and fair balance rather than quotability. The site was built to convert a visitor, never to be quoted by a machine.

The standard AEO advice, write fresh conversational answer content, makes the problem worse in pharma. New copy means new MLR review, and the review cycle is measured in months. Teams that follow generic AEO playbooks stall in exactly the place their agency can’t help them.

The process: assemble, don’t write

The approach that works inverts the playbook. You do not write AEO content for a regulated brand site. You assemble it from language that has already survived review. The work is structural, which is why it can move fast inside a compliance environment that otherwise moves slowly.

  1. Inventory the approved language. The prescribing information, the safety information, the claims matrix, the approved web copy. The operating rule is verbatim: no paraphrasing, no recombining claims into new sentences. If the answer a query deserves doesn’t exist in an approved source, that is a content request for the next review cycle, not a copywriting task for today.
  2. Separate audiences structurally. Patient and clinician assets carry an explicit audience tag through every block of structured data. Clinical depth never migrates into patient-facing assets, and plain-language framing never dilutes the HCP layer. Engines respect this separation when it’s machine-readable; reviewers require it.
  3. Build one entity graph, not page-by-page schema. A single canonical identity for the drug, the condition, and the manufacturer, reused identically across the patient and HCP properties, and connected to the registries engines already trust: DailyMed, ClinicalTrials.gov, FDA. Engines cite entities they can resolve. Most brand sites give them fragments.
  4. Keep fair balance inside the answer. Every benefit statement in an FAQ or answer block travels with its verbatim safety language, so that an engine lifting the answer lifts the balance with it. An extractable benefit claim without its balance is not an AEO win. It is a compliance incident with distribution.
  5. Validate, then measure citations like a channel. Structured data is validated against the schema vocabulary and Google’s rich-result requirements before anything ships. After launch, a standing query tracker runs the priority set across Google AI Overviews, ChatGPT, Perplexity, Gemini, and Copilot, scored monthly. We call the score the AI Visibility Index, and it gets reported like media performance, because that is what AI search now is.
01 Inventory the approved language PI, ISI, claims matrix, approved web copy 02 Separate audiences structurally Patient and clinician tags on every asset 03 Build one entity graph Canonical IDs, shared across properties 04 Keep fair balance inside the answer Benefit never travels without safety 05 Validate, then measure citations Query tracker across five engines

The assembly process. Nothing is written; everything is structured from language that already cleared review.

What it produced

For the oncology brand above, the assembly process took the AI Visibility Index from zero to 82 in 60 days, with the first Google AI Overview citation landing around week five. No new copy was written. Nothing waited on a full MLR cycle, because every string in the structured layer already carried approval.

AI Visibility Index, oncology brand, first 60 days 82 first AI Overview citation Day 0 Day 60

Index scores brand presence across Google AI Overviews, ChatGPT, Perplexity, Gemini, and Copilot against the priority query set. Same engagement as the case study on the AI & Search Visibility page.

What to do this week

Two checks, an afternoon of work. Run your priority queries and record how many trigger an AI answer. Then record whether your brand appears in them. If the first number is high and the second is near zero, your gap is structural, and the raw material to close it is already sitting in your approved-content library.

Presence in AI answers is being allocated right now, query by query, while most brand teams are still reporting rankings. The teams that treat the answer layer as a channel this year will be very hard to displace from it later.

← All thinking